Cargando…
Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
MB12066 is a molecule derived from β-lapachone that shown effects on obesity in previous studies. The present studies were conducted to evaluate the tolerability and pharmacokinetics (PK) of MB12066 after the oral administration of single and multiple doses to healthy volunteers. The study comprised...
Autores principales: | Kim, Seokuee, Lee, SeungHwan, Cho, Joo-Youn, Yoon, Seo Hyun, Jang, In-Jin, Yu, Kyung-Sang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683780/ https://www.ncbi.nlm.nih.gov/pubmed/29158665 http://dx.doi.org/10.2147/DDDT.S151269 |
Ejemplares similares
-
Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate
por: Lee, Hae Won, et al.
Publicado: (2017) -
Sulindac Compounds Facilitate the Cytotoxicity of β-Lapachone by Up-Regulation of NAD(P)H Quinone Oxidoreductase in Human Lung Cancer Cells
por: Kung, Hsiu-Ni, et al.
Publicado: (2014) -
Arylamino-nor-β-lapachone derivative-induced apoptosis in human prostate cancer cells: involvement of NAD(P)H:quinone oxidoreductase (NQO1)
por: Cavalcanti, Bruno C, et al.
Publicado: (2013) -
NAD(P)H: Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Polymorphisms in Papillary Thyroid Microcarcinoma: Correlation with Phenotype
por: Lee, Junguee, et al.
Publicado: (2013) -
Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family
por: Vasiliou, Vasilis, et al.
Publicado: (2006)